Latest MS Stories

Avanir Pharmaceuticals Announces Three Poster Presentations at Consortium of MS Centers Meeting Including Preliminary Results From PRISM Patient Registry

2012-06-01 02:25:02

ALISO VIEJO, Calif., June 1, 2012 /PRNewswire/ -- Avanir Pharmaceuticals, Inc. (NASDAQ: AVNR) today announced the presentation of three posters, including preliminary results from the PRISM patient registry, at the Fourth Cooperative Meeting of the Consortium of Multiple Sclerosis Centers (CMSC) and the Americas Committee for Treatment and Research in Multiple Sclerosis. PRISM Registry The aims of the PRISM registry are to define pseudobulbar affect (PBA) prevalence and its...

Making Connections Around The Globe to End MS

2012-05-30 02:25:48

On World MS Day, May 30, people from more than 70 countries are joining together to raise awareness and unite in the MS Movement NEW YORK, May 30, 2012 /PRNewswire-USNewswire/ -- Multiple sclerosis is a life altering disease that affects each person in a unique and different way. More than 2.1 million people worldwide live with MS, which is why demonstrating the power and importance of the global MS movement is critical on World MS Day, today -- May 30. (Logo:...

Health Canada Approves Updates to TYSABRI(R) (natalizumab) Product Monograph to Include Anti-JC Virus Antibody Status

2012-05-23 02:26:59

TORONTO, May 23, 2012 /CNW/ - Today Biogen Idec announced that Health Canada has approved a product monograph change for TYSABRI® that will help enable individual benefit risk assessment for patients with multiple sclerosis (MS). The new label identifies anti-JC virus (JCV) antibody status as a risk factor for developing an uncommon, but serious, brain infection known as progressive multifocal leukoencephalopathy (PML). This marks the third risk factor identified to help...

BIOCRATES Life Sciences to Launch Waters Xevo® TQ MS Editions for Two of its Well-established Research Kit Products, AbsoluteIDQ® p180 and p150

2012-05-21 02:24:48

VIENNA, May 21, 2012 /PRNewswire/ -- Austrian BIOCRATES Life Sciences AG, prime developer of state-of-the-art metabolite biomarker panels, is about to launch new editions of two of its well-established research kit products -AbsoluteIDQ(R) p180 and p150. Originally developed for use with the AB Sciex mass spectrometers, both kits are now available for Waters Xevo(R) TQ MS systems, greatly increasing sample throughput and accelerating up analytical processes....

Synthetic Biologics Reports First Quarter 2012 Financial Results

2012-05-15 10:24:49

ANN ARBOR, Mich., May 15, 2012 /PRNewswire/ -- Synthetic Biologics, Inc. (NYSE Amex: SYN), a developer of synthetic DNA-based therapeutics and innovative disease-modifying medicines for serious illnesses, today reported financial results for the three months ended March 31, 2012 and summarized operational highlights. Operational Highlights Management Team - Strengthened Clinical Development and Regulatory Affairs Functions Recruited former Chief Medical Officer of Clinical...

Smoking Cannabis Relieves Pain For Multiple Sclerosis Patients

2012-05-15 10:37:37

Connie K. Ho for RedOrbit.com The benefits and drawbacks of cannabis have long been discussed in the medical community. And now, a new study looks at how cannabis can affect the pain of multiple sclerosis (MS) patients. Many patients of MS report to have spasticity, which is a condition that makes their muscles tight and difficult to control. There are some drugs that are available, but many of these treatments tend to not show improvement in patients’ conditions. The report, recently...

TV host Phil Keoghan and professional women cyclists join Novartis to raise awareness of multiple sclerosis

2012-05-08 02:24:06

EAST HANOVER, N.J., May 8, 2012 /PRNewswire/ -- Phil Keoghan, host of "The Amazing Race," and the women cyclists of the professional "NOW and Novartis for MS" team are joining with Novartis Pharmaceuticals Corporation for a second year in a row to raise awareness of MS. The campaign, "Together in MS," will support the MS community and show that MS does not have to define the more than 400,000 people in the U.S. living with the disease. To view the multimedia assets associated...

Study Shows Halting An Enzyme Can Slow Multiple Sclerosis In Mice

2012-04-30 14:55:57

Researchers studying multiple sclerosis (MS) have long been looking for the specific molecules in the body that cause lesions in myelin, the fatty, insulating cells that sheathe the nerves. Nearly a decade ago, a group at Mayo Clinic found a new enzyme, called Kallikrein 6, that is present in abundance in MS lesions and blood samples and is associated with inflammation and demyelination in other neurodegenerative diseases. In a study published this month in Brain Pathology, the same group...

Leading Global Multiple Sclerosis Research Center Taps IBM Analytics to Improve Patient Care

2012-04-26 02:29:56

ARMONK, N.Y., April 26, 2012 /PRNewswire/ -- IBM (NYSE: IBM) today announced that researchers from The State University of New York (SUNY) at Buffalo are using IBM analytics technology to study more than 2,000 genetic and environmental factors that may contribute to multiple sclerosis (MS) symptoms. (Logo: http://photos.prnewswire.com/prnh/20090416/IBMLOGO) As part of the initiative, Researchers will tap into IBM's analytics technology to develop algorithms for big data...

Drug Reduces MS Likelihood

2012-04-23 04:45:20

(Ivanhoe Newswire) – According to a recent study, people who received injections of the multiple sclerosis (MS) drug interferon beta-1a directly after noticing signs of possible MS were less likely to progress into definite MS compared to those who switched to interferon beta-1a from placebo. Although it is not currently available in the United States, the trial was conducted with the human serum albumin-free formulation of interferon beta-1a, which is available in all European Union...